Showing results (151-160 of 537) with videos related to
Sort By:
Pageof 54
Blood|February 17, 2012
The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETOFu-Sheng Chou, Andrea Griesinger, Mark Wunderlich, et al.The Journal of Pharmacology and Experimental Therapeutics|January 7, 2005
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1Jim J Xiao, Amy B Foraker, Peter W Swaan, et al.British Journal of Haematology|June 10, 2025
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remissionJose Tinajero, Dat Ngo, Maria Motta, et al.Blood|July 23, 2016
CBFβ-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia initiation in miceQi Cai, Robin Jeannet, Wei-Kai Hua, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantationNavin Wadehra, Sherif Farag, Brian Bolwell, et al.Leukemia & Lymphoma|April 4, 2013
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101Jeffrey A Jones, Amy S Ruppert, Weiqiang Zhao, et al.Cancer Chemotherapy and Pharmacology|August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.Aging|July 30, 2020
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AMLFeiteng Huang, Jie Sun, Wei Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B studyKlaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.Proceedings of the National Academy of Sciences of the United States of America|December 17, 2014
Expression and prognostic impact of lncRNAs in acute myeloid leukemiaRamiro Garzon, Stefano Volinia, Dimitrios Papaioannou, et al.Pageof 54